Samuel J Klempner
Overview
Explore the profile of Samuel J Klempner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
4096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
41.
Maron S, Klempner S
Cancer Discov
. 2022 Mar;
12(3):602-603.
PMID: 35257152
Optimizing the utility of tumor mutational burden in solid tumors remains an unmet need and a clinical knowledge gap. Using a centrally determined cutoff of ≥16 mut/Mb, Friedman and colleagues...
42.
Myer P, Lee J, Madison R, Pradhan K, Newberg J, Isasi C, et al.
Cancer Discov
. 2022 Feb;
12(5):1282-1293.
PMID: 35176763
Significance: KRAS (particularly KRASG12D/G13), APC, and PIK3CA were more frequently altered in AFR who had a lower frequency of MSI-H tumors. There were no differences in actionable kinase driver alterations....
43.
Bhangoo M, Costantini C, Clifford B, Chung J, Schrock A, Ali S, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-7.
PMID: 35172493
No abstract available.
44.
Ajani J, DAmico T, Bentrem D, Chao J, Cooke D, Corvera C, et al.
J Natl Compr Canc Netw
. 2022 Feb;
20(2):167-192.
PMID: 35130500
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric...
45.
Fuca G, Cohen R, Lonardi S, Shitara K, Elez M, Fakih M, et al.
J Immunother Cancer
. 2022 Feb;
10(2).
PMID: 35110358
Background: Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance...
46.
Klempner S, Schrock A, Ali S, Kubicky C, Taylor M
JCO Precis Oncol
. 2022 Feb;
3:1-6.
PMID: 35100669
No abstract available.
47.
Chao J, He T, DApuzzo M, Chen Y, Frankel P, Tajon M, et al.
Adv Radiat Oncol
. 2022 Jan;
7(1):100807.
PMID: 35071830
Purpose: Single agent PD-1 inhibitors have yielded durable responses in a minority of gastroesophageal cancers. Radiation therapy has been recognized to promote antitumor immune responses and may synergize with anti-PD-1...
48.
Klempner S, Hendifar A, Waters K, Nissen N, Vail E, Tuli R, et al.
JCO Precis Oncol
. 2022 Jan;
4:614-619.
PMID: 35050748
No abstract available.
49.
Zhang L, Hamdani O, Gjoerup O, Cho-Phan C, Snider J, Castellanos E, et al.
JCO Precis Oncol
. 2022 Jan;
6:e2100330.
PMID: 35050711
Purpose: Human epidermal growth factor receptor 2 (HER2) overexpression or amplification (amp) are biomarkers for approved anti-HER2 therapies. amp may better predict response compared with immunohistochemistry or in situ hybridization,...
50.
Nagasaka M, Balmanoukian A, Madison R, Zhang S, Klempner S, Ou S
Lung Cancer
. 2022 Jan;
164:52-55.
PMID: 35032819
The sequential use of 1-/2-generation to 3-generation epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) has led to the emergence of triple EGFR mutations generally consisting of the founder mutation...